港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

生物醫藥B類股

575.900

-2.033-0.35%

漲家數：12

跌家數：19

平家數：3

市盈率：- -

高：598.497

開：578.227

低：573.488

收：577.933

成交量：1.14億

成交額：33.29億

市值：3,682.12億

流通市值：3,290.33億

資料載入中...

總覽新聞資訊

老百姓大藥房與信達生物深化戰略合作攜手共拓創新藥市場

新股消息 | 據報聞泰醫藥擬赴港上市募資規模約為1億至2億美元

沛嘉醫療(09996)發布2025年度業績：穩中求進、提質增效核心業務穩健增長

智通财经网

河北省定州市市場監管局開展醫療器械經營環節法規宣貫培訓

中国质量新闻网

康寧傑瑞公布2025年度業績及近期業務進展

漢方製藥獨家產品捲入行賄案上個月剛披露H股招股書

康方生物(09926)出現大手買入8.1萬股，成交價$124.3，涉資1.007千萬

阿斯达克财经

《大行》華泰證券：吉利德收購Ouro反映康諾亞(02162.HK)平台價值

阿斯达克财经

強業績提振，港股通創新藥逆市續漲，520880收復20日線！樂普生物-B績後狂飆14%

港股異動 | 基石藥業-B(02616)再升逾4% 核心商業化產品舒格利單抗獲ESMO指南【I, A】級推薦

港股沛嘉醫療-B早盤升逾6%

每日经济新闻

國家醫保局醫藥服務管理司司長黃心宇：長護險制度建設可以從市地級統籌先起步不搞「齊步走」、「一刀切」

開拓藥業－Ｂ(09939)股價下跌5.085%，現價港幣$2.8

阿斯达克财经

港股生物醫藥板塊漲幅居前，康方生物升逾5%，科倫博泰生物升逾4%

老虎资讯综合

快訊：恒指低開0.27% 科指跌0.68% 科網股走弱創新藥概念高開快手跌超9%

【券商聚焦】中信建投：醫療器械板塊拐點來臨，26年業績改善個股存在業績估值修復機會

雲頂新耀(01952)2025年股東淨虧損按年收窄71.4%

《業績》亞盛醫藥－Ｂ(06855.HK)去年虧損擴大至12.43億人民幣

阿斯达克财经

沛嘉醫療-B(09996.HK)：董事會董事長張一博士擬於公開市場繼續增持股份

亞盛醫藥-B(06855)雙引擎驅動高增長，耐立克銷售按年大增81%

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1574/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":575.89996,"timestamp":1774512265702,"preClose":577.93304,"halted":0,"volume":113603820,"delay":0,"changeRate":-0.003518,"floatShares":0,"shares":0,"eps":0,"marketStatus":"收市競價","change":-2.033081,"latestTime":"03-26 16:00:00","open":578.2267,"high":598.49725,"low":573.4878,"amount":3328626817,"amplitude":0.043274,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1774512600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1774488600000,1774497600000],[1774501200000,1774512000000]],"pbRate":5.179109,"peRate":-60.041027,"turnoverRate":0.004143,"increases":13,"decrements":20,"flats":0,"marketCap":368211528480,"floatMarketCap":329033220336},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":598.49725,"amplitude":0.043274,"preClose":577.93304,"low":573.4878,"pbRate":"5.179109","latestPrice":575.89996,"volume":113603820,"delay":0,"open":578.2267,"prevYearClose":556.26263,"prevWeekClose":560.669,"prevMonthClose":553.496,"prevQuarterClose":556.263,"fiveDayClose":571.212,"twentyDayClose":537.703,"sixtyDayClose":574.89,"secType":"PLATE","market":"HK","turnoverRate":0.004143,"peRate":-60.041027,"marketCap":368211528480,"floatMarketCap":329033220336,"timestamp":1774512265702,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":12,"down":19,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622783622","title":"老百姓大藥房與信達生物深化戰略合作 攜手共拓創新藥市場","url":"https://stock-news.laohu8.com/highlight/detail?id=2622783622","media":"证券日报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622783622?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 14:24","pubTimestamp":1774506240,"startTime":"0","endTime":"0","summary":"本报讯受处方外流持续推进影响，对于部分进院难度较大的创新药，零售药房已成为实现商业化落地、提升患者可及性的重要渠道。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603263685418646.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0502904849.HKD","BK1161","BK1589","603883","LU2097828474.EUR","LU2328871848.SGD","LU1969619763.USD","LU2488822045.USD","LU2097828631.EUR","LU0455707207.USD","LU2097828557.USD","BK1583","HK0000165453.HKD","BK0209","159992","LU2242644610.SGD","01801","06978","BK1574","LU2097828714.EUR","LU2097828805.USD"],"gpt_icon":0},{"id":"2622836858","title":"新股消息 | 據報聞泰醫藥擬赴港上市 募資規模約為1億至2億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622836858","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622836858?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 14:23","pubTimestamp":1774506210,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据媒体消息，成都闻泰医药科技股份有限公司Vincentage Pharma正考虑赴港上市，拟募资规模约为1亿至2亿美元。公司最受关注的管线是口服小分子GLP-1受体激动剂VCT220，也被称为CX11。公开信息显示，CX11已在中国进行II期临床试验，并显示出“有竞争力的减重效果”，其III期临床已于2024年底启动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419379.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1515","09939","BK1574","159938"],"gpt_icon":0},{"id":"2622833544","title":"沛嘉醫療(09996)發布2025年度業績：穩中求進、提質增效 核心業務穩健增長","url":"https://stock-news.laohu8.com/highlight/detail?id=2622833544","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622833544?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 13:16","pubTimestamp":1774502207,"startTime":"0","endTime":"0","summary":"3月25日，沛嘉医疗(09996)发布了截至2025年12月31日止十二个月(“报告期”)的年度业绩。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20260326/20260326131606_90636.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260326/20260326131606_90636.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419352.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["09996","159891","BK1100","BK1574","BK1583"],"gpt_icon":0},{"id":"2622833510","title":"河北省定州市市場監管局開展醫療器械經營環節法規宣貫培訓","url":"https://stock-news.laohu8.com/highlight/detail?id=2622833510","media":"中国质量新闻网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622833510?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 13:15","pubTimestamp":1774502100,"startTime":"0","endTime":"0","summary":"中国质量新闻网讯 为进一步规范医疗器械经营秩序，压实企业主体责任，保障公众用械安全，近期，河北省定州市市场监督管理局对全市156家医疗器械经营企业开展了三期医疗器械经营环节法规宣贯培训。下一步，该局将以此次培训宣贯为契机，压紧压实企业质量安全主体责任，不断强化医疗器械质量监管，依法严厉打击违法违规行为，切实保障公众用械安全。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-03-26/doc-inhshxny2864385.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1100","159883","09996","BK1574","BK1222","BK1583","09997"],"gpt_icon":0},{"id":"2622835709","title":"康寧傑瑞公布2025年度業績及近期業務進展","url":"https://stock-news.laohu8.com/highlight/detail?id=2622835709","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622835709?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 13:14","pubTimestamp":1774502040,"startTime":"0","endTime":"0","summary":"苏州2026年3月26日 /美通社/ -- 康宁杰瑞生物制药公布了截至2025年12月31日的2025年度业绩和近期业务进展。财务概览  2025年度实现营业收入566.24百万元人民币，其中归属于本公司的产品收入130.13百万元人民币。2025年度年内亏损113.95百万元人民币。财务状况安全稳健，截至2025年12月31日现金储备为1350.32百万元人民币。2025年4月，KN026联合白蛋白结合型多西他赛HB1801一线治疗HER2阳性复发转移性乳腺癌的Ⅲ期临床研究完成全部患者入组。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4919913_ZH19913_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4585","LU0348723411.USD","LU1992135399.USD","BK4148","BK1574","LU2322448957.HKD","LU1720051108.HKD","LU1992135472.HKD","LU1720051017.SGD","BK1161","09966","LU2272731600.USD","LU2473716301.USD","LU2357305700.SGD","BK4588","LU2272731782.SGD","LU2272731865.HKD","LU1548497426.USD","BK4512","LU2322448791.USD","IE00BFMHRM44.USD"],"gpt_icon":1},{"id":"2622887076","title":"漢方製藥獨家產品捲入行賄案 上個月剛披露H股招股書","url":"https://stock-news.laohu8.com/highlight/detail?id=2622887076","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622887076?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 11:37","pubTimestamp":1774496231,"startTime":"0","endTime":"0","summary":"中国经济网北京3月26日讯 国家医保局网站3月24日通报了“张某猛药品销售行贿案”。2024年10月，河北省秦皇岛市山海关区人民法院依法组成合议庭，适用普通程序公开开庭审理了张某猛行贿、对非国家工作人员行贿案。　　汉方制药于2月25日向港交所递交了招股书，拟于主板上市。据招股书显示，汉方制药成立于2004年，从事中医药产品研发、生产及销售业务。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202603/26/20260326934314.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202603/26/20260326934314.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260326/32100470.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1574","01477","BK1191"],"gpt_icon":0},{"id":"2622880365","title":"康方生物(09926)出現大手買入8.1萬股，成交價$124.3，涉資1.007千萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2622880365","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622880365?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 11:34","pubTimestamp":1774496040,"startTime":"0","endTime":"0","summary":"[大手成交]康方生物(09926)在上午11:34出现大手买入，成交量为8.1万，成交价为港币$124.3，涉资1.007千万。至目前为止，股价升2.053%，今日最高价为$129.7，而最低价为$124.1，总成交量为880.26万股，总成交金额港币$11.197亿。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180815142908460_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180815142908460_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2603265100/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2603265100/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["IE00B5MMRT66.SGD","09926","LU0634319403.HKD","LU2476274720.SGD","LU0417516902.SGD","IE00BPRC5H50.USD","LU0540923850.HKD","BK1161","LU0348825331.USD","LU0348783233.USD","LU0561508036.HKD","LU2399975544.HKD","LU1794554557.SGD","LU0348827113.USD","IE00B543WZ88.USD","LU0348735423.USD","LU1961090484.USD","LU0417516738.SGD","BK1574","LU0348766576.USD","LU0348784397.USD","LU0417516571.SGD","LU2476274308.USD","LU0348767384.USD","LU1720050803.USD","LU2778985437.USD","LU2488822045.USD"],"gpt_icon":0},{"id":"2622887191","title":"《大行》華泰證券：吉利德收購Ouro反映康諾亞(02162.HK)平台價值","url":"https://stock-news.laohu8.com/highlight/detail?id=2622887191","media":"阿斯达克财经","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622887191?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 11:21","pubTimestamp":1774495260,"startTime":"0","endTime":"0","summary":"华泰证券发表报告指，康诺亚-B公告吉利德将以16.75亿美元首付款、5亿美元里程碑并购Ouro，后者为承载CM336海外权益的NewCo。交易完成后，康诺亚依据Ouro股权将取得2.5亿元首付款及7,000万美元里程碑，同时继续享有CM336的销售分成权利。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220419164250683_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220419164250683_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1512718/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1512718/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0276","LU0531971595.HKD","BK1583","LU1934453819.USD","LU0164865239.USD","LU2148510915.USD","LU1064131003.USD","BK1574","BK1161","LU1328615791.USD","LU0871576103.HKD","LU1580142542.USD","BK0028","BK1587","LU1781817850.SGD","02162","601688","BK0188","LU1808992512.USD","BK0183","LU1979443071.USD","LU0039217434.USD","BK0012","LU1064130708.USD"],"gpt_icon":0},{"id":"2622882066","title":"強業績提振，港股通創新藥逆市續漲，520880收復20日線！樂普生物-B績後狂飆14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622882066","media":"新浪基金","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622882066?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 11:03","pubTimestamp":1774494180,"startTime":"0","endTime":"0","summary":"3月26日，港股通医药再度逆市表现，100%创新药研发标的——港股通创新药ETF华宝、港股医疗核心资产——港股通医疗ETF华宝双双高开，一度携手涨超1%！520880量价齐升，盘中收复20日线，实时成交超2亿元。　　创新药多股领跑，乐普生物-B盘中飙升逾14%站上半年线，领涨所有港股通标的。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-03-26/doc-inhshtfa2929921.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","VXUS","520880","06978","BK1574","02157","BK4585","BK4588","159992"],"gpt_icon":0},{"id":"2622821058","title":"港股異動 | 基石藥業-B(02616)再升逾4% 核心商業化產品舒格利單抗獲ESMO指南【I, A】級推薦","url":"https://stock-news.laohu8.com/highlight/detail?id=2622821058","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622821058?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 10:53","pubTimestamp":1774493593,"startTime":"0","endTime":"0","summary":"消息面上，3月25日，基石药业-B发布公告，公司核心商业化产品舒格利单抗获得欧洲肿瘤内科学会指南的级推荐。2025年2月，舒格利单抗联合化疗已获得ESMO《非驱动基因阳性转移性非小细胞肺癌动态临床指南》的推荐，用于鳞状及非鳞状IV期非小细胞肺癌双适应症的一线治疗。至此，舒格利单抗在欧盟及英国获批的两项肺癌适应症均已被纳入ESMO指南，充分体现了其临床价值。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419292.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4588","BK1574","BK4585","02616","VXUS"],"gpt_icon":0},{"id":"2622444882","title":"港股沛嘉醫療-B早盤升逾6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622444882","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622444882?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 10:47","pubTimestamp":1774493260,"startTime":"0","endTime":"0","summary":"每经AI快讯，3月26日，沛嘉医疗-B(09996.HK)早盘涨超6%，截至发稿涨6.69%，报6.06港元，成交额1185.39万港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603263685222031.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603263685222031.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159891","09996","BK4585","BK1100","BK4588","BK1583","VXUS","BK1574"],"gpt_icon":0},{"id":"2622882934","title":"國家醫保局醫藥服務管理司司長黃心宇：長護險制度建設可以從市地級統籌先起步 不搞「齊步走」、「一刀切」","url":"https://stock-news.laohu8.com/highlight/detail?id=2622882934","media":"金融一线","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622882934?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 10:46","pubTimestamp":1774493160,"startTime":"0","endTime":"0","summary":"3月26日金融一线消息，国务院新闻办公室举行新闻发布会，介绍加快建立长期护理保险制度有关情况。国家医保局医药服务管理司司长黄心宇在国新办新闻发布会上表示，《关于加快建立长期护理保险制度的意见》规定用三年左右的时间，基本建立适应我国基本国情的长期护理保险制度。到2028年底，这项制度要在全国基本上全面覆盖。\n　　黄心宇指出，从统筹层次上，可以从市地级统筹先起步，也可以根据当地实际情况探索省级统筹。有条件的市地可以先行，不具备条件的市地可以先夯实条件之后再实施，总的来说是不搞“齐步走”、不搞“一刀切”。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：秦艺","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jryx/insurance/2026-03-26/doc-inhshnwy0399508.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1574","09939","159938","BK1515"],"gpt_icon":0},{"id":"2622882993","title":"開拓藥業－Ｂ(09939)股價下跌5.085%，現價港幣$2.8","url":"https://stock-news.laohu8.com/highlight/detail?id=2622882993","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622882993?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 10:34","pubTimestamp":1774492440,"startTime":"0","endTime":"0","summary":"[下跌股]开拓药业－Ｂ(09939) 股价在上午10:34比前收市价下跌5.085%，现股价为港币$2.8。至目前为止，今日最高价为$2.95，而最低价为$2.8。总成交量为54.8万股，总成交金额为港币$156.63万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180725131625844_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180725131625844_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2603261531/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2603261531/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","BK1515","BK1161","09939"],"gpt_icon":0},{"id":"1112843274","title":"港股生物醫藥板塊漲幅居前，康方生物升逾5%，科倫博泰生物升逾4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1112843274","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112843274?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 09:54","pubTimestamp":1774490076,"startTime":"0","endTime":"0","summary":"3月26日，$生物(000504)$医药板块涨幅居前，$康方生物(09926)$涨超5%，$科伦博泰(06990)$生物涨超4%，$泰格医药(03347)$、$荣昌生物(09995)$涨超3%，$药明康德(02359)$、$君实生物(01877)$等个股跟涨","market":"us","thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0417516902.SGD","LU0348784397.USD","LU1961090484.USD","LU0348766576.USD","09926","02162","09995","BK4588","BK4581","LU2778985437.USD","LU1720050803.USD","01877","LU2476274308.USD","IE00B5MMRT66.SGD","BK1161","IE00BPRC5H50.USD","BK1574","LU0348783233.USD","LU0540923850.HKD","LU0348767384.USD","LU0417516738.SGD","BK4585","LU0634319403.HKD","LU2476274720.SGD","LU0348735423.USD","LU0561508036.HKD","LU2488822045.USD","LU2399975544.HKD","LU1794554557.SGD","LU0348827113.USD","IE00B543WZ88.USD","LU0348825331.USD","LU0417516571.SGD","03347"],"gpt_icon":0},{"id":"2622813298","title":"快訊：恒指低開0.27% 科指跌0.68% 科網股走弱 創新藥概念高開 快手跌超9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622813298","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622813298?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 09:20","pubTimestamp":1774488000,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　美股周三表现向上，中东局势有缓和迹象，油价由高位回落，带动大市气氛，三大指数均录得升幅收市。美元先跌后回升，美国十年期债息回落至4.33厘水平，金价反复向好，油价先跌后回稳。\n　　今日港股三大指数集体低开，恒指开盘跌0.27%，报25267.16点，恒科指跌0.68%，国企指数跌0.41%。盘面上，科网股涨跌不一，京东涨超2%，快手跌超9%，哔哩哔哩跌超1%；创新药概念股活跃，乐普生物涨超6%；汽车股部分走弱，蔚来跌超2%。\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：郝欣煜","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-03-26/doc-inhshnwy0334896.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0211977185.USD","LU1251922891.USD","LU1720050803.USD","LU1303224171.USD","HSTECH","LU0359201885.HKD","LU0572944931.SGD","BK1610","BK1590","HHImain","LU0359201612.USD","LU1719994722.HKD","MCHmain","BK1161","LU0348766576.USD","81024","BK1591","LU0348767384.USD","01024","LU2097828474.EUR","LU0326950275.SGD","LU1794554557.SGD","LU0588546209.SGD","LU2097828714.EUR","LU0210526637.USD","BK1574","LU2097828631.EUR","BK1615","LU0456827905.SGD","BK1608","513600","LU0051755006.USD","LU1770034418.SGD","LU0140636845.USD","LU0593848301.USD","LU0327786744.USD","LU0244354667.USD","LU1188198961.HKD","LU0359202008.SGD","LU1023057109.AUD","LU2097828557.USD","LU0307460666.USD","BK1575","BK1095","LU0463099449.HKD","LU2097828805.USD","02833","HSI"],"gpt_icon":0},{"id":"2622818008","title":"【券商聚焦】中信建投：醫療器械板塊拐點來臨，26年業績改善個股存在業績估值修復機會","url":"https://stock-news.laohu8.com/highlight/detail?id=2622818008","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622818008?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 09:18","pubTimestamp":1774487918,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投表示，医疗器械板块拐点来临，26年业绩改善个股存在业绩估值修复机会。建议持续关注市场空间大、国产化率低的创新器械赛道，以及并购重组、脑机接口、AI医疗、手术机器人、外骨骼机器人等主题方向的投资机会。潜在催化较多的方向有望出现涨幅数倍的个股，未来AI医疗、脑机接口等也有望成为投资人重点关注的新科技方向。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977292","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06826","BK1593","BK1574","601066","BK1571","BK1591","09997","BK1584","BK1502","BK1583","LU0173614495.USD","159883","01066","01302","BK1615","BK1142","BK1100","09996","BK1610","BK1600","02190","BK1222","02235","BK1515","BK1589","BK1585","BK1617","LU0287142896.SGD","BK1247","02252","BK1587","BK1501","BK1189","00853","BK1161","00241","BK0276"],"gpt_icon":0},{"id":"2622198889","title":"雲頂新耀(01952)2025年股東淨虧損按年收窄71.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622198889","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622198889?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 09:04","pubTimestamp":1774487064,"startTime":"0","endTime":"0","summary":"金吾财讯 | 云顶新耀(01952)公告发布，截至2025年12月31日止，公司母公司拥有人应占净亏损为2.98亿元(人民币，下同)，同比减亏71.4%，每股基本净亏损0.89元，同比减亏72.5%。期内，录得收益17.07亿元，同比增长1.41倍；毛利润11.82亿元，同比增长1.24倍。期内，集团研发开支5.11亿元，分销及销售开支7.81亿元，一般行政开支2.77亿元。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/MGVkMTYyODU4OTM2NDU2Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MGVkMTYyODU4OTM2NDU2Mg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977287","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","01952","BK1583"],"gpt_icon":0},{"id":"2622886079","title":"《業績》亞盛醫藥－Ｂ(06855.HK)去年虧損擴大至12.43億人民幣","url":"https://stock-news.laohu8.com/highlight/detail?id=2622886079","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622886079?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 08:52","pubTimestamp":1774486320,"startTime":"0","endTime":"0","summary":"亚盛医药－Ｂ(06855.HK) 公布截至去年12月底止全年业绩，营业额5.74亿元人民币(下同)，按年跌41.5%。亏损扩大至12.43亿元，上年同期蚀4.05亿元；每股亏损3.49元。不派末期息。(ca/w)(港股报价延迟最少十五分钟。沽空资料截至 2026-03-25 16:25。)过往派息公布日期派息事项派息内容2025/08/21中期业绩无派息2025/03/27末期业绩无派息2024/08/22中期业绩无派息2024/03/27末期业绩无派息AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20191016100749692_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20191016100749692_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1512620/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1512620/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["MCNHmain","CYB","06855","BK1574","CNHmain","UCmain","MUCmain","BK1161"],"gpt_icon":0},{"id":"2622883271","title":"沛嘉醫療-B(09996.HK)：董事會董事長張一博士擬於公開市場繼續增持股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2622883271","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622883271?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 07:37","pubTimestamp":1774481825,"startTime":"0","endTime":"0","summary":"格隆汇3月26日丨沛嘉医疗-B(09996.HK)发布公告，董事会获悉，执行董事、首席执行官兼董事会董事长张一博士(“张博士”)透过其所控制的公司，自2026年3月26日起拟于公开市场上继续购买公司股份。是次持股增加合共代价预期不超过1500万港元。\r\n\r\n　　经张博士告知，持股增加反映其对公司内在价值的认可，以及其对公司发展前景及增长潜力的坚定信心。张博士将不排除根据适用法律及法规于适当时候进一步增加其于公司持股的可能性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260326/32098777.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1100","BK1574","159891","BK1583","09996"],"gpt_icon":0},{"id":"2622588314","title":"亞盛醫藥-B(06855)雙引擎驅動高增長，耐立克銷售按年大增81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622588314","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622588314?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 07:28","pubTimestamp":1774481290,"startTime":"0","endTime":"0","summary":"3月26日，头部创新药企业亚盛医药发布2025年全年业绩。作为公司首款商业化产品，耐立克在2025年迎来医保落地后的首个完整销售年份，销售额实现显著增长，达到4.35亿元人民币，同比大幅增长81%。公司第二款产品、中国首个上市的国产原创Bcl-2抑制剂利生妥自2025年7月获批后快速放量，截至报告期末的5个月内实现销售额7058万元人民币。业绩增长由已上市的两大核心产品“双引擎”高效驱动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419181.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"亚盛医药-B(06855)双引擎驱动高增长，耐立克销售同比大增81%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AAPG","BK1574","BK4139","06855","BK1161"],"gpt_icon":0}],"pageSize":20,"totalPage":16,"pageCount":1,"totalSize":301,"code":"91000000","status":"200"}]}}